<--- Back to Details
First PageDocument Content
Mutation / Rat / LMNT / Dosing / Carcinogen / Biology / Medicine / Old World rats and mice / Micronucleus test
Date: 2013-11-12 10:15:02
Mutation
Rat
LMNT
Dosing
Carcinogen
Biology
Medicine
Old World rats and mice
Micronucleus test

6th IWGT Iguassu, Brazil Liver Micronucleus Test (LMNT) Subgroup  

Add to Reading List

Source URL: www.iaemgs.org

Download Document from Source Website

File Size: 1,34 MB

Share Document on Facebook

Similar Documents

Microsoft Word - VIS410 Phase 2a Trial Dosing Release FINAL

Microsoft Word - VIS410 Phase 2a Trial Dosing Release FINAL

DocID: 1veWX - View Document

Voluntary Recall: Lorazepam Oral Concentrate, USP 2mg/ml by Amneal Pharmaceuticals - Misprinted Dosing Droppers At PharmPix we are committed to the health and well-being of patients. It is for this reason that we inform

Voluntary Recall: Lorazepam Oral Concentrate, USP 2mg/ml by Amneal Pharmaceuticals - Misprinted Dosing Droppers At PharmPix we are committed to the health and well-being of patients. It is for this reason that we inform

DocID: 1vbgN - View Document

Methadone Dosing Guideline

Methadone Dosing Guideline

DocID: 1v2ad - View Document

Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of SEL-212: Monthly Dosing of SEL-212 Mitigates the Formation of Anti-Drug Antibodies and Enables Sustained Control of Serum Uric Acid in Symptomatic Gou

Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of SEL-212: Monthly Dosing of SEL-212 Mitigates the Formation of Anti-Drug Antibodies and Enables Sustained Control of Serum Uric Acid in Symptomatic Gou

DocID: 1uVOT - View Document

Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-D

Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-D

DocID: 1uNq4 - View Document